OMER
Omeros CorporationNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$828.68M
P/E Ratio
—
EPS
$-0.08
Beta
2.53
52W High
$17.65
52W Low
$2.95
50-Day MA
$11.36
200-Day MA
$7.92
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
9.39
PEG Ratio
0.81
About Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Fundamentals
| Revenue (TTM) | $-30.00M |
| Gross Profit (TTM) | $-35.63M |
| EBITDA | $-121.83M |
| Operating Margin | 0.00% |
| Return on Equity | -576.00% |
| Return on Assets | -25.50% |
| Revenue/Share (TTM) | $-0.48 |
| Book Value | $-1.69 |
| Price-to-Book | 8.44 |
| Price-to-Sales (TTM) | 4.43 |
| EV/Revenue | 7.77 |
| EV/EBITDA | -1.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 14.90% |
| Shares Outstanding | $72.00M |
| Float | $69.28M |
| % Insiders | 2.80% |
| % Institutions | 46.71% |
Analyst Ratings
Consensus ($38.00 target)
2
Buy2
HoldData last updated: 4/9/2026